Is Tesamorelin / Ipamorelin legal in Australia?

The clinic version of the growth hormone blend, pairing the one GHRH analogue with FDA approval against 806 patients of Phase 3 data with a ghrelin mimetic whose single human trial missed its endpoint. No study has tested the two together. On the common 5 mg plus 5 mg vial, reaching the 2 mg tesamorelin dose that produced the approved result also delivers 2 mg of ipamorelin, roughly seven to ten times the dose ipamorelin is used at alone.

This is the blend that gets prescribed rather than shipped in a plain box, and it is the one where the gap between component evidence and blend evidence is widest. Tesamorelin is a stabilised GHRH analogue approved as Egrifta.

Mechanism: Tesamorelin activates the pituitary GHRH receptor, raising the amplitude of endogenous growth hormone pulses while preserving hypothalamic feedback, which is the property that let it reduce visceral fat without the effects of giving growth hormone directly. Ipamorelin activates the ghrelin receptor GHS-R1a on the same cell, a separate pathway that also releases growth hormone and reduces somatostatin tone.

Regulatory history: Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy; ipamorelin is not approved and no combination product exists.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Tesamorelin / Ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.